Log in

VIMIAN Vimian Group AB OMXSTO · Sweden

Vimian Group AB (VIMIAN) news

Vimian Group AB is a public biotech or pharmaceutical company listed on OMXSTO under the ticker VIMIAN, recorded under Sweden. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest Vimian Group AB news

We have not published a story on Vimian Group AB yet. When there is news, it will appear here.

Questions about Vimian Group AB

What is the ticker symbol of Vimian Group AB?

Vimian Group AB trades under the ticker VIMIAN on OMXSTO.

Where is Vimian Group AB listed?

Vimian Group AB is listed on OMXSTO. Our directory also records these other listings: LSX:A3CSG7.

Which country or territory is Vimian Group AB listed under?

Our directory records Vimian Group AB under Sweden.

What does Vimian Group AB do?

Our directory classifies Vimian Group AB as: Biotechnology. This is a directory classification, not a description of the pipeline.

What is the ISIN of Vimian Group AB?

The ISIN recorded for Vimian Group AB is SE0015961982.

Does aibio.space cover Vimian Group AB?

aibio.space lists Vimian Group AB among 2,820 public biotech companies and publishes its news here as stories appear.

Which companies are similar to Vimian Group AB?

Companies in our directory listed in the same country and business area as Vimian Group AB: PILA PHARMA AB, DOUBLE BOND PHARMACEUTICAL INTERNATIONAL AB, Biovica International AB, Elicera Therapeutics AB, Active Biotech AB, BIO-WORKS TECHNOLOGIES AB.

Investor discussion: Vimian Group AB

Members talk about Vimian Group AB (VIMIAN). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open OMXSTO:VIMIAN on TradingView.

Listing details

Vimian Group AB is a public biotech or pharmaceutical company listed on OMXSTO under the ticker VIMIAN, recorded under Sweden. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
Vimian Group AB
Ticker
VIMIAN
Listing
OMXSTO
Country or territory
Sweden
Business scope
Biotechnology
ISIN
SE0015961982
Other listed symbols
LSX:A3CSG7
Last quote in directory
2026-10-21
Directory source
Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

aibio.space

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.